These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 30166326

  • 1. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
    Singh D, Abbott-Banner K, Bengtsson T, Newman K.
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166326
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP.
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [Abstract] [Full Text] [Related]

  • 3. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, Kerstjens HAM.
    Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
    [Abstract] [Full Text] [Related]

  • 4. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
    Pauwels R, Joos GF, Fogarty C, Faiferman I, Hirschberg S, Vessey R, Wouters EF.
    Pulm Pharmacol Ther; 2008 Sep; 21(2):385-92. PubMed ID: 18023600
    [Abstract] [Full Text] [Related]

  • 5. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
    Singh D, Zhu CQ, Sharma S, Church A, Kalberg CJ.
    Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
    [Abstract] [Full Text] [Related]

  • 6. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Norris V, Ambery C.
    Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
    [Abstract] [Full Text] [Related]

  • 7. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M, Santus P, D'Adda A, Pizzolato S, Di Marco F, Centanni S.
    Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
    [Abstract] [Full Text] [Related]

  • 8. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
    Pascoe S, Wu W, Zhu CQ, Singh D.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():2035-40. PubMed ID: 27621609
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A, Bhargava S, Singh V, Talwar D, Whig J, Rebello J, Purandare S, Gogtay J.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():1469-76. PubMed ID: 27418820
    [Abstract] [Full Text] [Related]

  • 10. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ.
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [Abstract] [Full Text] [Related]

  • 11. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
    Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT.
    Respir Res; 2020 Feb 10; 21(1):47. PubMed ID: 32041601
    [Abstract] [Full Text] [Related]

  • 12. Effects of short-acting bronchodilators added to maintenance tiotropium therapy.
    Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong JW, Lee A, Wijker SP, Cornelissen PJ.
    Chest; 2007 Nov 10; 132(5):1493-9. PubMed ID: 17890476
    [Abstract] [Full Text] [Related]

  • 13. Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma.
    Chhabra SK, Pandey KK.
    J Asthma; 2002 Aug 10; 39(5):375-81. PubMed ID: 12214891
    [Abstract] [Full Text] [Related]

  • 14. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
    Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, Rabe KF.
    Pulm Pharmacol Ther; 2003 Aug 10; 16(2):115-20. PubMed ID: 12670781
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B, Markham A.
    Drugs Aging; 2001 Aug 10; 18(6):441-72. PubMed ID: 11419918
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease.
    Wempe JB, Postma DS, Breederveld N, Kort E, van der Mark TW, Koëter GH.
    Thorax; 1992 Aug 10; 47(8):616-21. PubMed ID: 1412119
    [Abstract] [Full Text] [Related]

  • 20. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
    Chhabra SK, Vijayan VK, Vasu T.
    Indian J Chest Dis Allied Sci; 2006 Aug 10; 48(2):97-102. PubMed ID: 16696522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.